evipedia.ai
← Back

Bromantane for Health & Longevity

Evidence Review created on 08/15/2026 using AI4L / Opus 5

Also known as: Ladasten, Bromantan, Bromontan, N-(2-adamantyl)-N-(4-bromophenyl)amine

Motivation

Bromantane, sold in Russia under the trade name Ladasten, is a synthetic compound chemically related to the antiviral and Parkinson’s drug amantadine. It was developed in the Soviet Union to help soldiers and cosmonauts keep working through heat, thin air, and exhaustion, and it belongs to a small family of compounds designed to raise physical stamina without the racing, depleting quality of ordinary stimulants. What draws attention from people working on energy and stress resilience is an unusual claim: that it raises the brain’s own dopamine production rather than forcing dopamine out of storage.

The compound became widely known through sport. Several athletes tested positive at the 1996 Olympic Games in Atlanta, and it has been banned in competition ever since. In Russia it followed the opposite path, becoming an approved prescription treatment for states of persistent exhaustion. Nearly all human research on it was produced by the institute that developed it, and none of it has been repeated independently elsewhere.

This review examines what the human and animal evidence shows about bromantane’s effects on energy, mood, and stress resilience, what is known about its safety, how it has been used, and where the evidence stops.

Benefits - Risks - Protocol - Conclusion

This section collects sources that discuss bromantane, or the compound class it belongs to, in substantial depth and give a high-level view of the topic.

Fewer than five items are listed because the qualifying literature is genuinely small: outside four sources, the remaining material is either vendor-run sales content, encyclopedia and database entries, or Russian-language primary papers already represented above. The list has not been padded.

No content from any of the six priority experts or publications could be found. The likely reason is that bromantane has never been approved or marketed outside Russia and has no Western clinical trial record, so English-language longevity and performance outlets have had no regulatory or trial event to cover.

Grokipedia

Bromantane

A dense, heavily referenced overview covering chemistry, pharmacokinetics, the doping history, Russian regulatory status and grey-market use. Useful as an orientation map, though its claims trace back to the same small Russian literature.

Examine

No Examine article exists for bromantane.

Bromantane is a prescription medication in Russia and an unapproved drug elsewhere, not a dietary supplement; Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article exists for bromantane.

Bromantane is a prescription medication in Russia and an unapproved drug elsewhere, and no consumer supplement product containing it is legally marketed; ConsumerLab does not typically cover prescription medications.

Systematic Reviews

No systematic reviews or meta-analyses for Bromantane were found on PubMed as of August 15, 2026.

Neither side of the central trade-off is represented: there is no systematic review of the claimed benefit (relief of exhaustion states) and none of the principal risk (long-term effects of sustained dopamine-synthesis upregulation, or the anti-doping consequence).

Mechanism of Action

Bromantane’s core action is genomic rather than synaptic. A single dose increases transcription of tyrosine hydroxylase (the rate-limiting enzyme that starts dopamine production) and DOPA-decarboxylase (the enzyme that completes it) in the hypothalamus and striatum, raising dopamine and its immediate precursor (Vakhitova et al., 2004). Sampling of brain fluid in freely moving rats confirms prolonged dopamine release in the dorsal striatum (Grekhova et al., 1995).

It has no direct affinity for dopamine D1, D2 or D3 receptors or for the main serotonin receptor subtypes, and inhibits the dopamine transporter (the pump that recycles dopamine) only weakly — half-maximal inhibitory concentration 3.56 micromolar, roughly 125-fold weaker than the reference stimulant sydnocarb (Zimin et al., 2010). Two competing secondary explanations exist. One is GABA-ergic: reduced expression of transporters for GABA (gamma-aminobutyric acid, the brain’s main calming signal), plus protection of the receptor site that tranquilizers act on during stress (Iarkova et al., 2005). The other is epigenetic: falling histone deacetylase 1 (an enzyme that switches genes off) and altered histone marks in striatum and hippocampus (Salimgareeva et al., 2011).

It is fat-soluble and non-selective, 42% orally bioavailable, peaking at 2.75 hours in women and 4.0 hours in men, distributing into brain lipid and fat tissue, hydroxylated in the liver by cytochrome P450 enzymes (the body’s main drug-processing family; no specific member identified), and cleared slowly, with urinary metabolites detectable for two weeks. Half-life is reported as shorter in women, but no single figure is established (Oliynyk & Oh, 2012).

Historical Context & Evolution

Bromantane came out of a Soviet program that synthesized and screened 329 adamantane derivatives for compounds that would raise resistance to hostile conditions rather than act as direct stimulants; bromantane was selected for low toxicity and for accelerating recovery from fatigue, hyperthermia and low oxygen (Morozov et al., 1999). Its intended users were soldiers, cosmonauts and rescue workers, and it was deployed in the Soviet and later Russian armed forces to shorten recovery after heavy exertion (Oliynyk & Oh, 2012).

Its international debut was adversarial. Athletes tested positive at the 1996 Atlanta Games; the International Olympic Committee (IOC) treated it as a stimulant with masking properties, and it has been prohibited since 1997, now by the World Anti-Doping Agency (WADA) as a non-specified stimulant. Anti-doping bodies are publicly and government-funded regulators whose member organizations do not draw revenue from individual listing decisions; the same symmetry test applied to the other side of the dispute does not hold, since the Russian evidence base was produced by the compound’s developer and manufacturer.

Two of the 1996 disqualifications were set aside on appeal weeks later, the panel finding the compound unproven as a stimulant or masking agent. Both claims remain live: the animal endurance data are reproducible within Russian laboratories, and the human ergogenic data are thin. From 2006 onward the compound was redirected to civilian medicine and licensed in Russia for asthenia (persistent physical and mental exhaustion). Since the mid-2010s it has circulated in Western grey markets as a cognitive enhancer.

Expected Benefits

Medium 🟩 🟩

Reduction of Asthenic Symptoms

Asthenia is persistent exhaustion with poor concentration and low drive. In a 28-day randomized placebo-controlled trial in neurasthenia, bromantane reduced core asthenic symptoms faster and further than placebo (Neznamov et al., 2009). A 728-patient open-label multicenter study reported benefit from day three that persisted a month after withdrawal, alongside improved sleep and quality of life (Voznesenskaia et al., 2010). Both were run by the developing institute and its collaborators, who hold the commercial interest; the open-label design inflates apparent response.

Magnitude: In the 728-patient study, 76.0% of patients were rated responders on clinician-assessed severity and 90.8% on clinician-assessed improvement, with benefit appearing by day 3.

Anxiety Reduction Without Sedation

Unlike typical stimulants, bromantane appears to reduce anxiety while activating. A phase II trial in psychogenic asthenic disorder found a combined stimulant and anxiolytic (anxiety-reducing) profile, with the stimulant component dominant after single doses (Siuniakov et al., 2006). Animal work links the calming component to protection of the tranquilizer binding site on the GABA-A receptor during stress (Iarkova et al., 2005). The evidence rests on small trials run by the developer in a single diagnostic group.

Magnitude: Anxiety scores fell alongside asthenic symptoms in the same trials, without sedation or muscle relaxation; the literature reports no separate outcome figure for the anxiety component.

Low 🟩

Physical Work Capacity and Recovery Under Heat or Low Oxygen

In rodent swim and treadmill tests bromantane raised work output, speeded recovery from exhausting loads, and limited exercise-induced mitochondrial damage in heart and skeletal muscle (Morozov & Kleimenova, 1998). Human data are limited to Soviet heat-stress work (Badyshtov et al., 1995).

Magnitude: Rodent work capacity exceeded that of optimally dosed amphetamine by 1.3 to 1.6 times, with the effect lasting at least 24 hours after a single dose.

Attention and Operator Performance During Fatigue ⚠️ Conflicted

In ten healthy volunteers a single dose shifted brain electrical activity toward alert patterns and reduced tremor, but did not change subjective state or core task performance in unfatigued men (Viatleva et al., 2000). Patients’ self-ratings of a single test dose matched placebo on tolerability (Reutova et al., 2011).

Magnitude: Benefit is reported only in already-fatigued operators and not in rested ones; the literature reports no outcome figure for the size of the attention gain.

Durability of Effect Without Tolerance or Withdrawal

Across a 28-day course, stopping bromantane produced no withdrawal syndrome and no rebound worsening (Neznamov et al., 2009). A two-month rat course showed no loss of effect on physical and operant work capacity, and no dependence-related behavior after withdrawal (Iezhitsa et al., 2000).

Magnitude: No tolerance developed over two months of continuous rat dosing and no withdrawal syndrome followed 28 days of human dosing; the literature reports no figure for effect decay over time.

Speculative 🟨

Immune and Inflammatory Modulation

In mice given bacterial toxin, bromantane lowered TNF-α (tumor necrosis factor alpha, an inflammation signal) and interleukin-6 more than imipramine (Tallerova et al., 2011). No controlled human data exist; the basis is animal only.

Memory Consolidation and Synaptic Plasticity

In rat hippocampus, bromantane converted short-lasting synaptic strengthening into a long-lasting form, blocked by protein-synthesis and dopamine D1/D5 receptor inhibitors (Mikhaylova et al., 2007). No human memory trial exists; the basis is mechanistic.

Benefit-Modifying Factors

  • Baseline exhaustion level: The class effect is reported as strongest in people with low or middle resistance to stress and close to absent in the highly resistant (Oliynyk & Oh, 2012). Well-recovered, high-functioning users have the least headroom to gain.

  • Baseline brain-wave profile: Response direction tracked resting alpha rhythm. Patients with pronounced alpha rhythm got a predominantly stimulant effect, those with reduced alpha rhythm a predominantly calming one (Neznamov et al., 2008). Effect character is therefore individual, not fixed.

  • Sex-based differences: Absorption is faster in women, with peak blood levels at 2.75 hours versus 4.0 hours in men and a correspondingly shorter half-life (Oliynyk & Oh, 2012). Women may see earlier onset and shorter duration from the same dose.

  • Genetic polymorphisms: No pharmacogenetic study of bromantane exists. Because the effect runs through dopamine synthesis, variants in COMT (an enzyme that clears dopamine from the prefrontal cortex) and dopamine receptor density are plausible modifiers but are entirely untested here.

  • Pre-existing health conditions: Documented benefit is confined to diagnosed asthenia, neurasthenia and psychoautonomic syndrome (exhaustion with unstable heart rate and blood pressure) (Voznesenskaia et al., 2010). No trial has enrolled healthy high performers, so transfer of benefit to that group is an assumption.

  • Age-related considerations: Trial populations ran from adolescence to middle age. No data exist above roughly 65 years, where reduced dopamine synthesis capacity could either amplify benefit or narrow the margin before over-stimulation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Anti-Doping Rule Violation in Tested Athletes

Bromantane is prohibited in competition as a non-specified stimulant, a status dating from its detection in athletes at the 1996 Atlanta Games (Burnat et al., 1997). Because the molecule is highly fat-soluble and deposits in fat tissue, metabolites stay detectable in urine for around two weeks after a single dose (Oliynyk & Oh, 2012). For anyone competing in a tested sport this is near-certain rather than probabilistic, and a single course forecloses competition for weeks.

Magnitude: The urinary detection window is approximately 14 days after a single dose; five athletes were disqualified at the 1996 Games, two of them reinstated on appeal, and the prohibition has run continuously since 1997.

Medium 🟥 🟥

Insomnia, Headache and Irritability

The predictable consequence of raising dopamine signaling is over-activation. In the 728-patient multicenter study, adverse events were reported in about 3% of patients — chiefly difficulty sleeping, headache and irritability — with none rated serious and all dose-related (Voznesenskaia et al., 2010). That figure comes from an open-label study run by the compound’s developer and its collaborators, a design that systematically under-captures mild adverse events, and no independent post-marketing surveillance exists outside Russia.

Magnitude: Adverse events occurred in roughly 3% of 728 treated patients and 0.8% discontinued treatment; no serious adverse events were recorded over 28 days.

Low 🟥

Blood and Liver Changes at Supratherapeutic Doses

In rats dosed for months, exposures far above human therapeutic levels first raised and then depressed red cells, hemoglobin and white cells (Bugaeva et al., 1999). Reversible red-cell shape abnormality, enlarged liver cells and iron deposition in the spleen accompanied it. Nothing comparable is reported at human doses.

Magnitude: At 30 mg/kg hemoglobin and white cells rose; at 150 and 600 mg/kg both fell after three months — roughly 20 to 400 times the 50–100 mg human daily dose on a body-weight basis.

Dose-Dependent Behavioral and Thermoregulatory Disturbance

Rodent doses of 30–300 mg/kg stimulated behavior while 600 mg/kg and above suppressed it, with pupil dilation at all doses and body temperature falling 0.5–1 °C (Iezhitsa et al., 2002). A two-month course produced sex-divergent activity changes and appetite suppression (Iezhitsa et al., 2000).

Magnitude: Behavioral suppression begins above 600 mg/kg in rats, and rectal temperature dropped 0.5–1 °C across nearly all tested doses.

Reproductive and Developmental Uncertainty ⚠️ Conflicted

Maternal dosing before mating cut litter size by 34.9% and 44.2% at 30 and 600 mg/kg but raised it 45.1% at 150 mg/kg — a non-monotonic pattern that resists interpretation (Iezhitsa et al., 2001). A later group reported fewer resorptions (early embryo losses) and faster development (Bugaeva et al., 2012).

Magnitude: Litter size changed by −34.9%, +45.1% and −44.2% at 30, 150 and 600 mg/kg respectively; no human pregnancy data exist.

Cardiovascular and Autonomic Effects

In anesthetized rats bromantane raised stroke and minute blood volume while lowering heart rate and peripheral resistance, briefly and slightly raised arterial pressure, and weakly amplified the blood-pressure response to adrenaline and noradrenaline (Morozov et al., 2000). No human cardiovascular monitoring data are published.

Magnitude: Systemic arterial pressure rose only slightly and briefly in animals and urinary adrenaline and noradrenaline output fell; the literature reports no human blood-pressure figures.

Speculative 🟨

Grey-Market Product Quality

Outside Russia bromantane reaches users as an unregulated research chemical. A US forensic surveillance program first identified it in a toxicology case in October 2023; purity and dose accuracy cannot be assumed. Basis: surveillance only.

Unknown Consequences of Sustained Dopamine-Synthesis Upregulation

Bromantane raises the enzymes that build dopamine rather than releasing stored dopamine. Whether years of this alters receptor sensitivity or prolactin control is untested; no human study has run beyond 28 days. Basis: mechanistic reasoning.

Risk-Modifying Factors

  • Baseline blood and liver markers: The rodent target organs were blood-forming tissue and liver (Bugaeva et al., 1999). Pre-existing anemia, low white-cell counts or raised liver enzymes remove the margin that made those findings tolerable.

  • Sex-based differences: Two-month rat dosing lowered activity in males while leaving or raising it in females, and body weight rose in females and fell in males (Iezhitsa et al., 2000). Faster female absorption also concentrates peak exposure.

  • Pre-existing health conditions: Insomnia, anxiety disorders, bipolar disorder, uncontrolled hypertension and psychosis-spectrum conditions all sit downstream of raised dopamine tone and are the conditions most likely to worsen. None was studied.

  • Genetic polymorphisms: No variant has been tested against bromantane response or toxicity. Slow-clearance variants in liver drug-processing enzymes would prolong an already slowly eliminated, fat-stored compound, but the specific enzyme has not been identified.

  • Age-related considerations: Older adults carry more body fat relative to lean mass, which extends storage of a highly fat-soluble compound, and clear drugs more slowly. No participant above roughly 65 years has been studied.

Key Interactions & Contraindications

  • Dopaminergic drugs — caution: Levodopa, pramipexole, bupropion, selegiline and amantadine add to dopamine tone. Consequence: agitation, insomnia, nausea, raised blood pressure. Mitigation: combination is avoided; where unavoidable, a halved bromantane dose with blood-pressure monitoring applies.

  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline) — absolute contraindication: These block breakdown of the extra dopamine bromantane produces. Consequence: hypertensive crisis risk. Mitigation: complete avoidance, with a 14-day washout after an irreversible inhibitor is stopped.

  • Antipsychotics and dopamine blockers (haloperidol, risperidone, metoclopramide) — caution: Bromantane antagonizes neuroleptic effects in animals (Morozov et al., 1999). Consequence: loss of antipsychotic or anti-nausea control. Mitigation: avoidance; treatment goals directly conflict.

  • Barbiturates and drugs cleared by liver enzymes — monitor: Bromantane induces cytochrome P450 synthesis, shortening thiopental sleep time (Oliynyk & Oh, 2012). Consequence: reduced levels of warfarin, ciclosporin, hormonal contraceptives. Mitigation: separated dosing is useless; drug levels or effect are monitored.

  • Over-the-counter stimulants — caution: Caffeine, pseudoephedrine and phenylephrine add to activation and blood-pressure effect. Consequence: insomnia, palpitations, raised blood pressure. Mitigation: caffeine capped at 200 mg daily, with neither taken after midday.

  • Sedating antihistamines and sleep aids (diphenhydramine, doxylamine) — monitor: Bromantane antagonizes the sedative action of tranquilizers. Consequence: reduced sleep-aid efficacy, next-day sedation from escalating doses. Mitigation: moving bromantane earlier addresses the insomnia more directly than adding sedatives.

  • Supplements with additive dopaminergic effect — caution: L-Tyrosine, L-Phenylalanine and Mucuna pruriens supply substrate to the very enzymes bromantane upregulates. Consequence: over-stimulation, jaw tension, insomnia. Mitigation: omission during a course is simpler than titrating both.

  • Stimulant adaptogens (plant extracts taken to raise stress resistance) — monitor: Rhodiola rosea, Panax ginseng and high-dose ginkgo overlap in activation. Consequence: additive restlessness and disturbed sleep with no evidence of added benefit. Mitigation: one activating agent at a time.

  • 5-HTP (5-hydroxytryptophan, a serotonin building block) and serotonergic supplements — caution: Bromantane alters serotonin turnover in frontal cortex (Kudrin et al., 1995). Consequence: unpredictable mood and sleep effects. Mitigation: separation by weeks rather than hours, one at a time.

  • Heat and sauna protocols — monitor: The compound alters heat tolerance and thermoregulation (Badyshtov et al., 1995). Consequence: distorted heat-strain perception. Mitigation: sauna exposure shortened by a third on dosing days, with heart rate tracked rather than sensation.

Populations who should avoid Bromantane:

  • Athletes subject to anti-doping testing under any World Anti-Doping Agency code signatory, including masters and amateur competition
  • Pregnancy, active attempts to conceive, and breastfeeding — non-monotonic animal litter-size effects and zero human data
  • Anyone under 18 years
  • Bipolar disorder, or any psychosis-spectrum diagnosis, current or past
  • Uncontrolled hypertension (resting blood pressure above 160/100 mmHg) or arrhythmia
  • Active or recent liver disease (Child-Pugh Class B or C moderate-to-severe impairment, or alanine aminotransferase above three times the upper reference limit)
  • Baseline cytopenias (low blood cell counts) — hemoglobin below 11 g/dL, or white cells below 3.0 × 10⁹/L

Risk Mitigation Strategies

  • Anti-doping exposure confirmed first: Confirmation that no testing obligation applies for the next 30 days precedes any dose. This prevents the highest-probability harm — a sanctionable urinary finding persisting roughly 14 days after a single dose.

  • Low starting dose: The low end of the 50–100 mg daily range applies for the first week. Adverse events in the multicenter study were dose-related, so the lower dose reduces insomnia, headache and irritability.

  • Single morning dose before 12:00: The full dose falls in the morning. With peak blood levels at 2.75–4.0 hours and slow elimination, afternoon dosing is the main avoidable cause of the reported difficulty sleeping.

  • 28-day course cap: No human trial has run longer. A hard 28-day limit keeps exposure inside the only interval where the adverse-event rate has actually been measured.

  • Baseline and end-of-course blood work: Complete blood count and liver enzymes are drawn before starting and after each course, since blood-forming tissue and liver were the rodent toxicity targets.

  • Twice-weekly blood pressure tracking: Home readings on dosing days catch the blood-pressure amplification seen in animals. A resting systolic rise above 10 mmHg over baseline across two consecutive weeks is the stopping threshold.

  • Single-agent use: Combining bromantane with other stimulants, dopaminergic supplements or amino-acid precursors during a course is avoided. This prevents over-stimulation and keeps any adverse event attributable to a single agent.

  • Lot-specific certificate of analysis: Third-party identity and purity testing tied to the batch number addresses the adulteration and dose-accuracy risk inherent in unregulated grey-market supply.

Therapeutic Protocol

  • Standard Russian regimen: The registered protocol is 50–100 mg by mouth daily for up to 28 days, established in the multicenter asthenia study run by the developing institute’s clinical collaborators (Voznesenskaia et al., 2010).

  • Originating groups: The dosing was set by I. S. Morozov’s adamantane program and S. B. Seredenin’s group at the Zakusov Institute of Pharmacology in Moscow, who developed the compound and hold the commercial interest in it.

  • Competing approach — conventional wakefulness agents: Prescribed modafinil, methylphenidate or amantadine for fatigue states rest on registered Western trials, though a Phase 3 comparison found none beat placebo for multiple-sclerosis fatigue (NCT03185065).

  • Competing approach — non-drug first: Sleep-extension, graded exercise and iron or thyroid correction address common reversible causes of exhaustion, are unrestricted in sport, and carry no unregulated-supply risk. Neither approach is established as the default.

  • Best time of day: Morning, before 12:00. Peak blood levels arrive 2.75 hours after dosing in women and 4.0 hours in men (Oliynyk & Oh, 2012), placing peak activation in the working day.

  • Half-life and duration: No single half-life figure is established; it is reported as shorter in women, and effects on dopamine release persist far beyond the blood curve, with urinary metabolites present up to two weeks.

  • Single versus split dosing: Single morning dosing is standard and matches the registered regimen. Splitting is not described in any trial and pushes exposure into the evening, where it works against sleep.

  • Genetic polymorphisms: No pharmacogenetic data exist. Neither COMT nor dopamine receptor variants have been tested, so no genotype-guided dose adjustment can be justified beyond the general low-start principle.

  • Sex-based differences: Women absorb faster and eliminate faster (Oliynyk & Oh, 2012). The practical consequence is earlier onset and a shorter working window, not a different milligram dose.

  • Age-related considerations: No participant above roughly 65 years has been studied. Higher body-fat fraction and slower clearance argue for the 50 mg end and longer washouts in older users.

  • Baseline biomarker levels: Response was strongest where baseline exhaustion was greatest and near-absent in the highly stress-resistant (Oliynyk & Oh, 2012), so documented baseline fatigue is the main response predictor.

  • Pre-existing conditions: All trial evidence comes from diagnosed asthenia, neurasthenia or psychoautonomic syndrome. Use in the absence of a fatigue syndrome is an extrapolation with no supporting dose-finding work.

Discontinuation & Cycling

  • Short-term, not lifelong: Every human protocol is a defined 28-day course, not continuous therapy. No study supports indefinite use, and the registered indication is an episodic exhaustion state rather than a chronic condition.

  • No withdrawal syndrome reported: The randomized placebo-controlled trial included a final placebo week specifically to look for withdrawal effects and found none (Neznamov et al., 2009). Rat withdrawal after two months showed no dependence behavior.

  • No taper required: Because no rebound was observed, abrupt cessation at the end of a course is the tested approach. Tapering has never been studied and adds exposure days without a demonstrated benefit.

  • Effect outlasts the course: Antiasthenic benefit persisted for one month after stopping in the 728-patient study (Voznesenskaia et al., 2010), so the post-course window is not a period of lost effect.

  • Cycling rather than continuous use: Since benefit persists roughly a month and tolerance was absent over two months in rats, a 28-day course followed by at least 28 days off preserves effect while capping cumulative exposure.

Sourcing and Quality

  • Only one pharmaceutical-grade product exists: Ladasten, the Russian registered 50 mg tablet, is the sole form manufactured to pharmacopeial standards. Everything sold elsewhere is bulk research chemical, not a finished medicine.

  • What to look for: A lot-specific certificate of analysis from an independent laboratory, showing identity by nuclear magnetic resonance or mass spectrometry and purity by chromatography above 98%, with the batch number matching the container.

  • Certificate mills are the main trap: Undated certificates, certificates without a batch number, and vendor-generated documents carry no assurance. A named, independently contactable testing laboratory is the distinguishing feature.

  • No third-party certification program covers it: Neither ConsumerLab, NSF nor Informed Sport tests bromantane products, because it is not a legal dietary supplement anywhere. No brand or compounding pharmacy has an established quality record for it.

  • Formulation matters for absorption: The compound is virtually insoluble in water and only 42% bioavailable (Oliynyk & Oh, 2012). Solutions in carrier oils and tablets differ in absorbed dose, so milligram equivalence across formats cannot be assumed.

Practical Considerations

  • Time to effect: Antiasthenic effects appeared by day 3 and built over the first two weeks in the multicenter study (Voznesenskaia et al., 2010). This is not an acute-dose compound, and judging it on day one is premature.

  • Regulatory status: Prescription-only in Russia; an unapproved new drug in the United States, not scheduled but not legal to sell for human consumption; tracked by forensic new-psychoactive-substance surveillance programs; prohibited in sport by the World Anti-Doping Agency.

  • Common pitfall — dose escalation: Because onset is slow and subtle, users raise the dose expecting a stimulant sensation. Adverse events were dose-related, so escalation converts a low-adverse-event compound into an insomnia and irritability problem.

  • Common pitfall — redosing in the afternoon: Slow elimination means an additional afternoon dose lands in the sleep window. Sleep disruption is the most reported adverse event and is largely self-inflicted through timing.

  • Common pitfall — continuous use: Treating it as a daily nootropic ignores that the entire human safety record stops at 28 days. Extended use is unmeasured territory, not an established maintenance protocol.

  • Cost and accessibility: Cost is not the barrier — grey-market supply runs roughly one to two dollars per day. Access, legality and unverifiable quality are the real constraints outside Russia.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. Raised dopamine tone delays sleep onset when dosed late, and difficulty sleeping was among the most reported adverse events; yet the multicenter study reported normalization of the sleep-wake cycle in exhausted patients (Voznesenskaia et al., 2010). Practical rule: dosing before 12:00, with insomnia read as a timing error first.

  • Nutrition: Indirect and potentiating. The compound raises the enzymes that convert tyrosine into dopamine, so protein-adequate intake supplies substrate, while isolated L-Tyrosine supplements risk over-stimulation. Its near-insolubility in water and high fat solubility mean a meal containing fat is the more reliable way to take it.

  • Exercise: Direct and potentiating for recovery. Rodent work showed faster recovery from exhausting loads and protection of muscle and heart mitochondria (Morozov & Kleimenova, 1998). It does not blunt hypertrophy by any known mechanism, but it disqualifies tested athletes, which overrides any training benefit.

  • Stress management: Direct and blunting of the stress response. In stress-susceptible rats it prevented stress-induced disruption of the receptor site that tranquilizers act on (Iarkova et al., 2005). It complements rather than replaces breathing, meditation and load management, and no human cortisol data exist.

Monitoring Protocol & Defining Success

A baseline before a first course covers a complete blood count, liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), resting blood pressure and heart rate measured at home across three mornings, and prolactin (a pituitary hormone that dopamine suppresses). A written baseline of fatigue, sleep and mood belongs alongside it, since the primary outcome is symptomatic rather than biochemical. Blood work repeats at the end of each 28-day course, then every 6–12 months where courses are repeated. Blood pressure and heart rate are recorded twice weekly throughout each course, and again one week after stopping. The rationale is narrow and specific: rodent toxicity concentrated in blood-forming tissue and liver, and the animal cardiovascular signal was a mild amplification of the blood-pressure response, so these are the only parameters with a mechanistic reason to move.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin Men 14.0–15.5 g/dL; women 13.0–14.5 g/dL Blood-forming tissue was the rodent toxicity target Conventional labs flag only below 13.5 (men) and 12.0 (women); pair with ferritin if falling
White blood cell count 4.5–7.5 × 10⁹/L Detects the white-cell suppression seen at high rodent doses Conventional range extends to 11.0 × 10⁹/L; a differential count is needed, not the total alone
Alanine aminotransferase (ALT) Men below 25 U/L; women below 20 U/L Liver was a rodent target organ and the site of metabolism Conventional upper limits of 40–55 U/L are far too permissive; an 8–12 hour fast and no hard training for 48 hours beforehand
Aspartate aminotransferase (AST) Below 25 U/L Pairs with ALT to separate liver from muscle origin Rises with exercise; interpretable only alongside ALT and a muscle-enzyme test
Prolactin Within the laboratory reference interval Dopamine suppresses prolactin, so it tracks dopaminergic tone No established on-treatment target exists; change from the individual’s own baseline is what is tracked. Drawn before 10:00, fasted, after 30 minutes rest
Resting blood pressure Below 120/80 mmHg Animals showed weak amplification of the blood-pressure response Home morning readings, seated, three-day average; a sustained rise above 10 mmHg systolic is the stop signal

Qualitative markers matter more than any laboratory value here, because the only demonstrated benefit is symptomatic. Weekly tracking covers:

  • Time from waking to feeling functionally alert
  • Number of days per week with an afternoon energy collapse
  • Sleep onset latency and number of night awakenings
  • Capacity to start difficult tasks without external pressure
  • Irritability and background tension, rated simply
  • Training-session recovery time compared with the pre-course baseline

Emerging Research

  • No registered trial exists: A ClinicalTrials.gov search on 15 August 2026 for bromantane, ladasten and actoprotector returned zero studies, ongoing or completed. For a compound in clinical use since the 1990s, this absence is itself the central finding.

  • Closest registered evidence, negative: NCT03185065, a Phase 3 Johns Hopkins trial of 141 patients, compared methylphenidate, modafinil and amantadine against placebo for multiple-sclerosis fatigue using a fatigue impact scale as primary endpoint.

  • Closest registered evidence, adamantane family: NCT06055244, a completed Phase 2 Ohio State study of 64 patients, tested amantadine for cognitive impairment in long COVID — the nearest registered test of this chemical family against a fatigue-cognition endpoint.

  • Epigenetic mechanism could strengthen the case: A single dose lowered histone deacetylase 1 and altered histone marks in striatum and hippocampus (Salimgareeva et al., 2011). If replicated independently, this would explain effects outlasting the drug’s presence.

  • Neuroimmune direction could strengthen the case: Ladasten corrected T-lymphocyte subpopulation shifts in an anxious-depressive mouse model (Tallerova et al., 2014), pointing toward inflammation-driven fatigue as a mechanism worth testing in humans.

  • Independent replication could weaken the case: Every positive human result comes from one institutional network with a commercial interest, and even its own placebo-controlled single-dose analysis found self-rated tolerability no different from placebo (Reutova et al., 2011).

  • Receptor pharmacology could weaken the case: Bromantane binds no dopamine or serotonin receptor directly and inhibits the dopamine transporter only weakly (Zimin et al., 2010), leaving the size of any human dopaminergic effect genuinely open.

  • Surveillance data will decide the safety question: Forensic monitoring first identified bromantane in a US toxicology case in October 2023, confirmed March 2024 (NPS Discovery monograph). Grey-market exposure at scale is now the de facto safety study, and its adverse-event signal will emerge there first.

Conclusion

Bromantane is a Soviet-developed compound that appears to raise the brain’s own dopamine production rather than force stored dopamine out, and it carries a claim that is unusual and worth taking seriously: activation without the crash, the tolerance, or the withdrawal that define ordinary stimulants. The human evidence points in a consistent direction — meaningful relief of persistent exhaustion, a calming rather than jittery quality, and side effects limited to disturbed sleep, headache and irritability in a small minority.

The problem is who produced that evidence. Almost all of it comes from the institute that created the compound and from its commercial collaborators, in most of it both the patients and the doctors knew who was getting the drug, and none of it has been repeated by an independent group anywhere. One placebo-controlled trial exists. Nothing has run longer than four weeks. The animal work is more varied, and its reproductive findings move in contradictory directions that no one has resolved.

For someone optimizing energy and stress resilience, that combination is genuinely awkward: a plausible mechanism and a clean short-term safety record, resting on a body of work that has never been independently checked. Anyone who competes under anti-doping rules faces a separate and near-certain problem, since traces persist for about two weeks. Outside Russia, quality of supply is unverifiable, which adds an uncertainty that has nothing to do with the compound itself.

Top - Benefits - Risks - Protocol